InterAx Biotech Ltd Company

InterAx Biotech Ltd is a Swiss biotech company that was incorporated in 2016 as a spinoff of ETH Zurich and Paul Scherrer Institute. They are working to revolutionize drug discovery by combining experimental assays, mathematical modeling, and artificial intelligence to analyze and predict the physiological response of cells to drugs. Their goal is to significantly reduce the time and costs associated with drug discovery and development for a wide range of human diseases. They integrate experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates.


Invests into


Connections